Christoph B. Olivier, Annabel Hölzle/LinkedIn
Mar 13, 2026, 22:05
Christoph B. Olivier: Annabel Hölzle Shared Critical Findings on HALT After TAVR
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared on LinkedIn, adding:
”Congratulations Annabel for an outstanding presentation at the Spring School 2026!
Today Annabel Hölzle shared critical findings from her study: ‘Periprocedural hemostatic and inflammatory changes after TAVR and their association with hypoattenuating leaflet thickening (HALT).’
Her research provides vital clues to improve long-term patient safety in heart valve interventions.
We are very proud to see our team members leading such high-impact clinical discussions.
Great job, Annabel!”

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events